Drug Trial Radar · NCT03891862
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
Last checked: Nov 20, 2026Latest source record: Apr 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
135
Actual
Start
Mar 18, 2019
Primary completion
Dec 23, 2019
Study completion Jan 30, 2020
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Mar 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.
Conditions
- Tardive Dyskinesia (TD)
Interventions
ValbenazineDrug
vesicular monoamine transporter 2 (VMAT2) inhibitor
Placebo oral capsuleDrug
non-active dosage form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Randomization (Week 8) in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 16Time frame: Week 8, Week 16
Locations
43 sites in 2 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Little Rock, Arkansas
Neurocrine Clinical Site
Anaheim, California
Neurocrine Clinical Site
Anaheim, California
Neurocrine Clinical Site
Costa Mesa, California
Neurocrine Clinical Site
Escondido, California
Neurocrine Clinical Site
Fountain Valley, California
Neurocrine Clinical Site
Glendale, California
Neurocrine Clinical Site
La Habra, California
Neurocrine Clinical Site
Lemon Grove, California
Neurocrine Clinical Site
Norwalk, California
Neurocrine Clinical Site
San Bernardino, California
Neurocrine Clinical Site
San Diego, California
Neurocrine Clinical Site
Torrance, California
Neurocrine Clinical Site
Pueblo, Colorado
Neurocrine Clinical Site
Hialeah, Florida
Neurocrine Clinical Site
Hialeah, Florida
Neurocrine Clinical Site
Hialeah, Florida
Neurocrine Clinical Site
Miami, Florida
Neurocrine Clinical Site
North Miami, Florida
Neurocrine Clinical Site
Orlando, Florida
Neurocrine Clinical Site
South Bend, Indiana
Neurocrine Clinical Site
Bloomfield Hills, Michigan
Neurocrine Clinical Site
East Lansing, Michigan
Neurocrine Clinical Site
Grand Rapids, Michigan
Neurocrine Clinical Site
Kansas City, Missouri
Neurocrine Clinical Site
St Louis, Missouri
Neurocrine Clinical Site
Lincoln, Nebraska
Neurocrine Clinical Site
Las Vegas, Nevada
Neurocrine Clinical Site
New York, New York
Neurocrine Clinical Site
Beachwood, Ohio
Neurocrine Clinical Site
Mason, Ohio
Neurocrine Clinical Site
Oklahoma City, Oklahoma
Neurocrine Clinical Site
Conshohocken, Pennsylvania
Neurocrine Clinical Site
Scranton, Pennsylvania
Neurocrine Clinical Site
Franklin, Tennessee
Neurocrine Clinical Site
DeSoto, Texas
Neurocrine Clinical Site
Houston, Texas
Neurocrine Clinical Site
Houston, Texas
Neurocrine Clinical Site
Irving, Texas
Neurocrine Clinical Site
Richmond, Texas
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.